Multikinase inhibitors: a new option for the treatment of thyroid cancer. - Wikidata - awgldk - TriplyDB

Multikinase inhibitors: a new option for the treatment of thyroid cancer.

Multikinase inhibitors: a new option for the treatment of thyroid cancer.

http://www.wikidata.org/entity/Q37921602

about

RET gene abnormalities and thyroid disease: who should be screened and when Lenvatinib for the treatment of radioiodine-refractory differentiated thyroid carcinoma: a systematic review and indirect comparison with sorafenib.RET fusion gene: translation to personalized lung cancer therapy Sorafenib in radioactive iodine-refractory well-differentiated metastatic thyroid cancer.A potential role for immunotherapy in thyroid cancer by enhancing NY-ESO-1 cancer antigen expression Antitumor activity of lenvatinib (e7080): an angiogenesis inhibitor that targets multiple receptor tyrosine kinases in preclinical human thyroid cancer models Evaluation of expression and function of vascular endothelial growth factor receptor 2, platelet derived growth factor receptors-alpha and -beta, KIT, and RET in canine apocrine gland anal sac adenocarcinoma and thyroid carcinoma Molecular pathogenesis and targeted therapies in well-differentiated thyroid carcinoma Molecular targets of naturopathy in cancer research: bridge to modern medicine.New therapies for dedifferentiated papillary thyroid cancer Incidence and risk of hand-foot skin reaction with cabozantinib, a novel multikinase inhibitor: a meta-analysis.Identification of Novel Small Molecule Inhibitors of Oncogenic RET Kinase.Hepatocellular Shuttling and Recirculation of Sorafenib-Glucuronide Is Dependent on Abcc2, Abcc3, and Oatp1a/1b.Novel tricyclic indeno[2,1-d]pyrimidines with dual antiangiogenic and cytotoxic activities as potent antitumor agents.Lipoteichoic acid induces surfactant protein-A biosynthesis in human alveolar type II epithelial cells through activating the MEK1/2-ERK1/2-NF-κB pathway.A phase 2 trial of lenvatinib (E7080) in advanced, progressive, radioiodine-refractory, differentiated thyroid cancer: A clinical outcomes and biomarker assessment Model-based treatment optimization of a novel VEGFR inhibitor.RAF kinase inhibitor-independent constitutive activation of Yes-associated protein 1 promotes tumor progression in thyroid cancer Specific delivery of kinase inhibitors in nonmalignant and malignant diseases.FGF receptor inhibitors: role in cancer therapy.Vandetanib: in medullary thyroid cancer.Pharmacokinetic evaluation of cabozantinib for the treatment of thyroid cancer.Significant associations between X-ray repair cross-complementing group 3 genetic polymorphisms and thyroid cancer risk.Central role of RET in thyroid cancer.Association between TP53 Arg72Pro polymorphism and thyroid carcinoma risk.Vandetanib for the treatment of thyroid cancer: an update.Selective use of vandetanib in the treatment of thyroid cancer.PDGFRα Regulates Follicular Cell Differentiation Driving Treatment Resistance and Disease Recurrence in Papillary Thyroid Cancer.Targeted near infrared hyperthermia combined with immune stimulation for optimized therapeutic efficacy in thyroid cancer treatment.The safety of vandetanib for the treatment of thyroid cancer.The safety and efficacy of vandetanib in the treatment of progressive medullary thyroid cancer.Platelet-derived growth factor receptor-α promotes lymphatic metastases in papillary thyroid cancer.Novel therapeutic clues in thyroid carcinomas: The role of targeting cancer stem cells.FAK Expression, Not Kinase Activity, Is a Key Mediator of Thyroid Tumorigenesis and Protumorigenic Processes.Treatment of advanced medullary thyroid cancer.Efficacy of sorafenib in advanced differentiated and medullary thyroid cancer: experience in a Turkish population Genetic and clinical features of multiple endocrine neoplasia types 1 and 2.Clinical outcome, role of BRAF(V600E), and molecular pathways in papillary thyroid microcarcinoma: is it an indolent cancer or an early stage of papillary thyroid cancer?Clinical guidance for radioiodine refractory differentiated thyroid cancer.Therapeutic effects of adenovirus-mediated CD and NIS expression combined with Na131I/5-FC on human thyroid cancer.

P2860

Q28709562-43BE3BF6-072E-4A15-BA55-F81FA4546CED Q30243995-10190180-49C1-4062-902A-E9D79BC68C9C Q33711282-E7FD84DB-79ED-4B77-843E-322625E4DC23 Q33927272-E7D429AF-2D67-434E-AA35-EF5090F31E94 Q33931434-05C6A708-7797-4F4A-8D4C-9550B70BD9AE Q34253418-130982DB-E0A6-49DC-90DC-89481050D8F8 Q34282488-6E1C0077-5B51-4DF5-A114-CC1DFA2FB53B Q34318833-3BFBDE57-5D05-4FE3-B4CF-DFE8DFF6FD2B Q34457265-737709C2-6498-4DB6-BEFA-C6F977419500 Q35381593-1F3B9FDF-5272-4BCE-87C8-F02BBB00F14F Q35640953-5C65E63F-48F0-4AE3-9800-4BD5AB0E818D Q35653681-EFB14421-F2EE-4D41-8378-0D44C0CFF4E9 Q35812091-C8E2EA27-BED2-4F80-84D4-923E2C611B34 Q36096646-90A2B2C6-302D-4B0C-B354-BE6E8C06ECD9 Q36380223-75882040-6527-4C2B-BDFF-698059D00090 Q36716739-90C21C8B-D2A9-4B95-949F-57805D6CA38D Q36779136-AB5F8C9F-3F07-4117-B210-2CDE9B67470F Q37087082-5C78BFD2-FF06-478B-936F-9D728FFC8646 Q37960141-DCE4E2FB-2E35-437B-8535-76C32811E3CE Q37981986-98D92034-2D3F-43BE-AFAF-D3BF9F34D4A7 Q38020194-DCCB7CD3-0845-4585-AE25-74524C94C059 Q38089099-7AEBBC71-D916-4E34-9DAE-5816D9FE13C0 Q38166311-0F88E7BC-39CC-41F2-A69B-1AA373101F60 Q38167995-E3362A6E-681E-47F7-9300-4D1C0000A522 Q38174500-BA6C6695-A5DC-4340-A6C5-1318EDC815E7 Q38185691-D1E16B3B-BE3A-49CA-805C-4208800E0CE1 Q38546474-74DE2940-B979-4F75-A1E7-CECFDBDE2DBD Q38737667-E5EDBCFA-E86F-487B-9190-14AC034EE743 Q38803440-74B236DC-E381-4B35-999A-6D25A3721FFE Q38864998-DA5BC006-3262-4452-889C-0DF4D56D580A Q38960074-EC7EDF30-39D1-46CD-8DD6-C41ED9B1FB5B Q39323181-3BF40065-445B-43BC-9E67-3A55B01BF8D2 Q39354316-86A99F20-42AB-4BFF-B784-FE89AA3F3AF2 Q39711361-3B6EA8EE-84E9-44EA-9068-D0B3ABDA5638 Q41043040-E7CF7F2C-7880-44DB-A2AC-BB3872137817 Q41639995-31C1E59A-BBD9-405C-B4AE-CFD81184156D Q41667928-00CCF738-71BB-4DA8-9707-E43402865053 Q42174969-76D32F6F-360A-4800-BECC-F2A8935B1493 Q47863818-4079EEDB-CEE5-4780-B14A-4FD55D7DE112 Q49207200-7065A9C6-D0EE-47E0-B1F1-5A0579198915

P2860

Multikinase inhibitors: a new option for the treatment of thyroid cancer.

http://www.wikidata.org/entity/Q37921602

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Multikinase inhibitors: a new option for the treatment of thyroid cancer.

@en

Multikinase inhibitors: a new option for the treatment of thyroid cancer.

@nl

type

label

Multikinase inhibitors: a new option for the treatment of thyroid cancer.

@en

Multikinase inhibitors: a new option for the treatment of thyroid cancer.

@nl

prefLabel

Multikinase inhibitors: a new option for the treatment of thyroid cancer.

@en

Multikinase inhibitors: a new option for the treatment of thyroid cancer.

@nl

P1433

Q37921602-BC5B9C52-5AA7-4D28-B960-E29E06133D7F

P1476

Q37921602-9322E816-9A76-4B5F-AD20-A13BC5BB4416

P2093

Q37921602-13375D6D-E1A6-4438-AED3-CE26534D8213

Q37921602-326063A1-F599-4032-BD08-AEE8E410AA32

Q37921602-85BAAA65-5C0B-4F68-A9A0-C5C4610E9A6F

P2860

Q37921602-00ADDA98-8D09-4A08-BDD9-07124A7AFEC3

Q37921602-01C05F68-A682-4E20-8FD8-0491452809F9

Q37921602-07B09C03-0A68-441F-B15C-4BE167F6FE23

Q37921602-0AC8A0C4-E842-4DAB-9C0A-08DC5D4965FB

Q37921602-0EB75044-4825-4854-B78E-56C512BCDD08

Q37921602-1076E72F-6B5C-45B4-BC44-866882E9A6B3

Q37921602-126A01C9-76CE-4C27-9278-06AF04699B24

Q37921602-17386C8C-CBBC-479C-BB2C-AA14E4B847D3

Q37921602-17E2D29E-13A9-4CE7-8826-56CFE3A89A9A

Q37921602-2A3EAAE2-8B60-47E4-9485-4A890C73C90C

P2888

Q37921602-E928B70C-AB2A-4D28-AAAF-92FF03C5D3EF

P304

Q37921602-DE32B088-7AD6-4203-A0E3-FA1B7AF81873

P31

Q37921602-4F59B163-6907-4753-B10E-1947E46E6E48

P356

Q37921602-6C9C30C0-2A81-4FA7-8BF3-1D83017700F8

P433

Q37921602-E7953773-667E-4208-B7A8-A16559F623E1

P478

Q37921602-80F5A8DF-E4F9-4F9F-8A93-E53ED2F43B64

P50

Q37921602-A2926C8B-E512-4C86-9EC5-E4EB9C3F5DCB

P577

Q37921602-86A1525C-AC79-4466-A39B-2314BEE359A4

P698

Q37921602-61365E43-D9C3-4A7F-ACCD-2E899703ED3D

P921

Q37921602-5049EDC0-B08E-4BB3-A5A9-1FED0D56090E

P356

NRENDO.2011.141

P1433

Nature Reviews Endocrinology

P1476

Multikinase inhibitors: a new option for the treatment of thyroid cancer

@en

P2093

Bruce G Robinson

http://www.w3.org/2001/XMLSchema#string

Martyn Bullock

http://www.w3.org/2001/XMLSchema#string

Matti L Gild

http://www.w3.org/2001/XMLSchema#string

P2860

Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers

Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

Mutations of the BRAF gene in human cancer

The sodium/iodide Symporter (NIS): characterization, regulation, and medical significance

Oncogenic BRAF regulates melanoma proliferation through the lineage specific factor MITF.

Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma.

Treatment options for patients with chronic myeloid leukemia who are resistant to or unable to tolerate imatinib

P2888

nrendo.2011.141

P304

617-624

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/NRENDO.2011.141

http://www.w3.org/2001/XMLSchema#string

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

7

http://www.w3.org/2001/XMLSchema#string

P50

Roderick J Clifton-Bligh

P577

2011-08-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21862995

http://www.w3.org/2001/XMLSchema#string

P921